Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunotherapy for the Treatment of Advanced Solid Tumor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03658785
Recruitment Status : Not yet recruiting
First Posted : September 5, 2018
Last Update Posted : September 7, 2018
Sponsor:
Information provided by (Responsible Party):
Wang Hui,MD, Tongji Hospital

Brief Summary:
The purpose of this study is to evaluate the safety, side effects and benefits of autologous tumor infiltrating lymphocytes(TIL) specific to personalized Neo-antigens in the treatment of patients with recurrent, metastatic and advanced solid tumors.

Condition or disease Intervention/treatment Phase
Recurrence Tumor Metastatic Cancer Solid Tumor Biological: TIL Drug: Aldesleukin Drug: Cyclophosphamide Drug: Fludarabine Phase 1 Phase 2

Detailed Description:
Adoptive cell transfer therapy that utilizes an autologous TIL manufacturing progress is originally developed by the NCI for the treatment of patients with recurrent, metastatic cervical cancer. TILs specific to personalized neo-antigens will be expended in vitro and given back to the patients through vein. A total of 20 patients will be enrolled in the single-arm, open label, interventional study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen for the Treatment of Advanced Solid Tumor
Estimated Study Start Date : December 10, 2018
Estimated Primary Completion Date : December 31, 2023
Estimated Study Completion Date : December 31, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: TIL,IL-2,Cyclophosphamide,Fludarabine

Biological: TIL On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine).

Drug: Aldesleukin Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every eight hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses.) Drug: Cyclophosphamide On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.

Drug: Fludarabine Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days.

Biological: TIL
On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine)

Drug: Aldesleukin
Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every eight hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses.)
Other Name: IL-2

Drug: Cyclophosphamide
On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
Other Name: CTX

Drug: Fludarabine
Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days




Primary Outcome Measures :
  1. Objective Responce Rate [ Time Frame: 6 months after cell infusion ]
    The Objective Responce Rate of patients received immunotherapy are accesed by the Response Criteria in Solid Tumors (RECIST) v1.0.


Secondary Outcome Measures :
  1. Adverse Event [ Time Frame: up to 12 months ]
    Aggregate of all adverse events, as well as their frequency and severity are accessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.03).

  2. Disease Control Rate [ Time Frame: up to 12 months ]
    Disease control rate (DCR) as measured by RECIST 1.1 criteria.

  3. Duration of Response [ Time Frame: up to 12 months ]
    Duration of response (DOR) as measured by RECIST 1.1 criteria .

  4. Progression-Free Survival [ Time Frame: up to 12 months ]
    PFS will be summarized using Kaplan-Meier estimates.

  5. Overall Survival [ Time Frame: up to 60 months ]
    The overall survival of all patients entering the study will be monitored.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

To be eligible for the study, patients must meet ALL of the following criteria prior to enrollment in the study:

  1. Must be ≥ 18 years of age at the time of consent.
  2. Must have recurrent, metastatic, or persistent carcinoma that is not amenable to curative treatment with surgery and/or radiation therapy and for which no other therapies are expected to have significant benefit, in the opinion of the Investigator.
  3. Must have at least 1 lesion that is resectable for TIL generation. The resected TIL generating lesion(s) should yield at least 1.5 cm in diameter post-resection of tumor tissue. Following resection for TIL generation, must have a remaining measurable target lesion as defined by RECIST v1.1.
  4. Patients must have progressive disease while receiving or after the completion of the most recent prior treatment.
  5. Any prior therapy directed at the malignant tumor must be discontinued at least 28 days prior to tumor resection. Radiation therapy may have been received up to 28 days prior to tumor resection for lesions not expected to be used for TIL generation or target lesions.
  6. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  7. Patients must be seronegative for the human immunodeficiency virus (HIV).
  8. Patients with positive serology for hepatitis B virus surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), or hepatitis C virus (anti-HCV) indicating acute or chronic infection may be enrolled if the viral load by polymerase chain reaction (PCR) is undetectable with/without active treatment.
  9. Hematology:

    Absolute neutrophil count greater than 1000/mm(3) without the support of filgrastim;White blood cell (WBC) greater than or equal to 3000/mm(3);Platelet count greater than or equal too 100,000/mm(3);Hemoglobin greater than 8.0 g/dl.

  10. Chemistry:

    Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than or equal to to 2.5 times the upper limit of normal. Serum creatinine less than or equal to to 1.6 mg/dl.Total bilirubin less that or equal to 1.5 mg/dl, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.

  11. Women of child bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus.

Exclusion Criteria:

  1. Patients who have received an organ allograft or prior cell transfer therapy.
  2. Patients who are on a systemic steroid therapy > 10 mg of prednisone daily or other steroid equivalent.
  3. Patients who currently have prior therapy-related toxicities greater than Grade 1 according to NCI-CTCAE v4.03; except for peripheral neuropathy, alopecia, or vitiligo prior to enrollment/resection.
  4. Patients who have a contraindication to or history of hypersensitivity reaction to any component or excipients of the TIL therapy and the other study drugs.
  5. Patients with active systemic infections, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory, or immune system.
  6. Patients with symptomatic and/or untreated brain metastases (of any size and any number).
  7. Patients who have any form of primary or acquired immunodeficiency syndrome, such as severe combined immunodeficiency disease or acquired immune deficiency syndrome (AIDS).
  8. Patients who have a diagnosis of end-stage renal disorder requiring hemodialysis.
  9. Patients who have a left ventricular ejection fraction (LVEF) < 45% or who are New York Heart Association (NYHA) Class 2 or higher.

    Patients who have a forced expiratory volume in 1 second (FEV1) of less than or equal to 60% of predicted normal.

  10. Patients who have received a live or attenuated vaccine within 28 days of the NMA-LD regimen.
  11. Patients whose cancer requires immediate treatment or who would otherwise suffer a disadvantage by participating in this study.
  12. Patients who have received prior treatment with immunotherapy (eg, anti-PD-1 anti-PD-L1, or anti-CTLA4 antibodies)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03658785


Contacts
Layout table for location contacts
Contact: Hui Wang, MD +8613995688388 huit71@sohu.com

Locations
Layout table for location information
China, Hubei
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Recruiting
Wuhan, Hubei, China, 430000
Contact: Wang         
Sponsors and Collaborators
Tongji Hospital
Investigators
Layout table for investigator information
Study Chair: Hui Wang, MD Tongji Hospital

Publications:
Layout table for additonal information
Responsible Party: Wang Hui,MD, Vice Director of Deparment of Gynecology and Obstetrics, Tongji Hospital
ClinicalTrials.gov Identifier: NCT03658785     History of Changes
Other Study ID Numbers: 2018TNB-V01
First Posted: September 5, 2018    Key Record Dates
Last Update Posted: September 7, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Wang Hui,MD, Tongji Hospital:
TIL
neo-antigen

Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Neoplasm Metastasis
Recurrence
Disease Attributes
Pathologic Processes
Neoplastic Processes
Cyclophosphamide
Fludarabine phosphate
Fludarabine
Aldesleukin
Vidarabine
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites, Antineoplastic
Antimetabolites
Antiviral Agents
Anti-Infective Agents
Anti-HIV Agents
Anti-Retroviral Agents